Any current/future new fundraising through debt or equity?

Currently, Valiant Organics has term loans amounting to ₹113 crores and is not looking to take any further loans in the near future. The company aims to continue repaying and reducing its debt as per the existing repayment schedule until FY '26. Debt-free status is unlikely soon, as future big CAPEX may require additional term loans. Cash flows are expected to improve once PAP ramp-up generates adequate accruals. Regarding equity fundraising, specifically the IPO of Valiant Laboratories (formerly Bharat Chemicals), the management has not disclosed detailed information as discussions are ongoin

Any current/future capex/capital investment/strategic investment?

Pharma Intermediates project: CAPEX of around ₹80-85 crores has been committed; currently at pilot stage with scope to expand (Page 15). PAP plant: Additional CAPEX planned to convert batch process into semi-continuous; CAPEX not significant (Page 17). No major new CAPEX planned in near future; future large CAPEX possible 2-3 years down the line (Page 13, 6). Current debt repayment plan ongoing until FY '26; future CAPEX may lead to additional term loans (Page 6). Focus on ramping up existing projects like PAP and Pharma Intermediates rather than fresh large investments immediately (Page 6, 12

Future growth expectations in sales/revenue/volumes?

PAP (Paracetamol raw material) production expected to ramp up from 400+ MT/month to around 800-900 MT/month, contributing 20-30% to total revenue in next 2-3 years. FY '24 revenue guidance is flattish at around Rs. 900-950 crores due to subdued demand in dyes intermediates and ongoing ramp-up of Sarigam plant. 20-25% growth anticipated in FY '24 driven by PAP ramp-up and pharma intermediates project becoming operational. Focus on stabilizing and optimizing capacity utilization (80-85%) in existing and new plants like PAP and pharma intermediates over next 1-2 years. Medium to long-term outlook

Future growth expectations in earnings/operating earnings/profits/EPS?

FY '24 expected growth: 20%-25%, driven by PAP ramp-up and Pharma intermediates stabilization. Operating margins targeted conservatively at 18%-20%, with long-term EBITDA margins projected between 20%-22%. PAP production aims to reach optimal capacity (~800-900 MT/month), contributing 20%-22% to FY '24 revenue, potentially rising to 30% at full capacity. Pharma Intermediates project (CAPEX ~Rs. 80-85 crores) currently in pilot stage with asset turns below 1x; expected to scale up within a year to 70%-80% utilization. Asset turnover for Pharma project expected to improve post-pilot phas

Current/ Expected Orderbook/ Pending Orders?

The transcript does not provide specific details on the current or expected order book or pending orders for Valiant Organics Ltd. Management mentions experimenting with product identification at the pharma intermediates pilot plant, indicating ongoing efforts to establish orders. Demand outlook for key sectors such as dyes, pigments, and pharma intermediates is cautiously expected to improve in coming quarters, particularly for PAP and chlorination products. Orders in the dyes and intermediates segment are currently subdued due to low industry demand and Eurozone challenges; improvement is ex

Valiant Organics LtdQ3 FY23Chemicals & Petrochemicals

Valiant Organics Ltd Q3 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹477P/E: 22.8Market Cap: ₹1.2K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 4

PAP (Paracetamol raw material) production expected to ramp up from 400+ MT/month to around 800-900 MT/month, contributing 20-30% to total revenue in next 2-3 years.
FY '24 revenue guidance is flattish at around Rs. 900-950 crores due to subdued demand in dyes intermediates and ongoing ramp-up of Sarigam plant.
20-25% growth anticipated in FY '24 driven by PAP ramp-up and pharma intermediates project becoming operational.
Focus on stabilizing and optimizing capacity utilization (80-85%) in existing and new plants like PAP and pharma intermediates over next 1-2 years.
Medium to long-term outlook positive with expected industry tailwinds (China plus 1 strategy, Indian specialty chemical sector growth).
Emphasis on expanding production capacity cautiously with efforts to improve asset turnover and margins around 18-22% EBITDA.
Pilot pharma intermediates plant expected to scale up commercially in about a year with utilization at 70-80%.

Margin guidance

Category 3

FY '24 expected growth: 20%-25%, driven by PAP ramp-up and Pharma intermediates stabilization.
Operating margins targeted conservatively at 18%-20%, with long-term EBITDA margins projected between 20%-22%.
PAP production aims to reach optimal capacity (~800-900 MT/month), contributing 20%-22% to FY '24 revenue, potentially rising to 30% at full capacity.
Pharma Intermediates project (CAPEX ~Rs. 80-85 crores) currently in pilot stage with asset turns below 1x; expected to scale up within a year to 70%-80% utilization.
Asset turnover for Pharma project expected to improve post-pilot phase, but exact ratio uncertain due to campaign-based multi-product operation.
Debt reduction ongoing with no new loans planned near-term; cash flows expected to improve as projects stabilize.
Long-term focus on improving ROE from current lower levels to ~20% initially, with further enhancement over 2-3 years.
Revenue guidance for FY '24 is flattish, estimated Rs. 900-950 crores due to current market conditions and ramp-up timelines.

See what Valiant Organics Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes

Currently, Valiant Organics has term loans amounting to ₹113 crores and is not looking to take any further loans in the near future.
The company aims to continue repaying and reducing its debt as per the existing repayment schedule until FY '26.
Debt-free status is unlikely soon, as future big CAPEX may require additional term loans.
Cash flows are expected to improve once PAP ramp-up generates adequate accruals.
Regarding equity fundraising, specifically the IPO of Valiant Laboratories (formerly Bharat Chemicals), the management has not disclosed detailed information as discussions are ongoing and sensitive due to competitive reasons.
No explicit timelines or plans for the IPO or other equity fundraising were shared during the call.

Order book

The transcript does not provide specific details on the current or expected order book or pending orders for Valiant Organics Ltd.
Management mentions experimenting with product identification at the pharma intermediates pilot plant, indicating ongoing efforts to establish orders.
Demand outlook for key sectors such as dyes, pigments, and pharma intermediates is cautiously expected to improve in coming quarters, particularly for PAP and chlorination products.
Orders in the dyes and intermediates segment are currently subdued due to low industry demand and Eurozone challenges; improvement is expected in a quarter or two.
Most PAP production is supplied to a subsidiary making paracetamol, ensuring steady internal demand with around 10% sold externally.
No direct quantitative order book or pending orders information was discussed in the Q&A or management commentary.

See what Valiant Organics Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

Pharma Intermediates project: CAPEX of around ₹80-85 crores has been committed; currently at pilot stage with scope to expand (Page 15).
PAP plant: Additional CAPEX planned to convert batch process into semi-continuous; CAPEX not significant (Page 17).
No major new CAPEX planned in near future; future large CAPEX possible 2-3 years down the line (Page 13, 6).
Current debt repayment plan ongoing until FY '26; future CAPEX may lead to additional term loans (Page 6).
Focus on ramping up existing projects like PAP and Pharma Intermediates rather than fresh large investments immediately (Page 6, 12).
Discussions ongoing on new product development and chlorination expansion, likely 2 years out (Page 13).

Track Valiant Organics Ltd — get its next earnings analysis in your feed

How does Valiant Organics Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

ThisValiant Organics Ltd

Rev 4Mar 3

See where Valiant Organics Ltd sits in Chemicals & PetrochemicalsSee which companies these are, and every other name in the sector.Open rankings

How does Valiant Organics Ltd rank in Chemicals & Petrochemicals?

Compare Valiant Organics Ltd against every Chemicals & Petrochemicals company (Q3 FY23) on revenue, margins and earnings-call signals.

View Chemicals & Petrochemicals leaderboard →

What Valiant Organics Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

Prasol Chemicals Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹433.6 crores . Key investor presentation takeaways from Prasol Chemicals Ltd's Q1 FY27 investor presentation — and how it rank
Vipul Organics Ltd (Q4 FY26)
Q4 FY26 (Mar 2026) total revenue: ₹5,262.37 lakhs (Consolidated) . Key concall takeaways from Vipul Organics's Q4 FY26 earnings call — and how it ranks against…
Vipul Organics Ltd (Q1 FY27)
Q1 FY27 net revenue: ₹51.78 crore, up +37.7% YoY (Page 13) . Key concall takeaways from Vipul Organics's Q1 FY27 earnings call — and how it ranks against…
Fine Organic Industries Ltd (Q1 FY27)
Revenue from Operations (Consolidated) for Q1FY27: Rs 694.2 Cr, up 18.0% YoY from Rs 588.4 Cr in Q1FY26 (Page 34). Key concall takeaways from Fine Organic…

Compare:vs Solar Industries India Ltd vs Pidilite Inds.vs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →